NDAORALTABLET
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
ACTICLATE (doxycycline hyclate) by Molecular Devices is 12. Approved for gonorrhea, chlamydia, syphilis and 2 more indications. First approved in 2014.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTICLATE (doxycycline hyclate) is an oral tetracycline-class antibiotic that inhibits bacterial protein synthesis and is indicated for sexually transmitted infections (gonorrhea, chlamydia, syphilis), acne vulgaris, and other bacterial infections. Peak plasma levels are achieved within 3 hours, with a serum half-life of 18-22 hours, allowing for convenient dosing regimens.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), suggesting stable commercial operations and established team infrastructure.
Mechanism of Action
12.1 Mechanism of Action Doxycycline is a tetracycline-class antimicrobial drug [see ] . 12.3 Pharmacokinetics Absorption Doxycycline hyclate tablets: Following administration of a single 300 mg dose to adult volunteers, average peak plasma doxycycline levels were 3.0 mcg per mL at 3 hours,…
Worked on ACTICLATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.